World Journal of
Gastroenterology

World Journal of Gastroenterology

WJG

Contents

Contents

ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, Alfred Gangl, MD, Emeritus Professor, Department of Medicine 3, Division of Gastroenterology and Hepatology, Medical University of Vienna, Allgemeines Krankenhaus, Vienna A-1090, Austria

AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (*WJG*, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

 WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The *WJG* is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Scopus. The 2019 edition of Journal Citation Report® cites the 2018 impact factor for *WJG* as 3.411 (5-year impact factor: 3.579), ranking *WJG* as 35th among 84 journals in gastroenterology and hepatology (quartile in category Q2). CiteScore (2018): 3.43.

RESPONSIBLE EDITORS FOR THIS ISSUE

Observational Study

Impact of *GFRA1* gene reactivation by DNA demethylation on prognosis of patients with metastatic colon cancer

Wan-Ru Ma, Peng Xu, Zhao-Jun Liu, Jing Zhou, Lian-Kun Gu, Jun Zhang, Da-Jun Deng

ORCID number: Wan-Ru Ma (0000-0002-9697-7355); Peng Xu (0000-0002-7559-8559); Zhao-Jun Liu (0000-0003-0924-7862); Jing Zhou (0000-0001-9814-6574); Lian-Kun Gu (0000-0003-0791-1280); Jun Zhang (0000-0001-9796-994X); Da-Jun Deng (0000-0001-5161-5943).

Wan-Ru Ma, Zhao-Jun Liu, Jing Zhou, Lian-Kun Gu, Da-Jun Deng, Key Laboratory of Carcinogenesis and Translational Research (MOE/Beijing), Division of Etiology, Peking University Cancer Hospital and Institute, Beijing 100143, China

Peng Xu, Jun Zhang, Shihezi University School of Medicine, Shihezi 832000, Xinjiang Uygur Autonomous Region, China

Peng Xu, Morphological Center of Basic Medical School of Xinjiang Medical University, Urumqi 830011, Xinjiang Uygur Autonomous Region, China

Corresponding author: Da-Jun Deng, MD, Professor, Laboratory of Carcinogenesis and Translational Research (MOE/Beijing), Division of Etiology, Peking University Cancer Hospital and Institute, No. 52, Fucheng Road, Haidian District, Beijing 100142, China. deng-dajun@bjmu.edu.cn

Abstract

BACKGROUND
The expression of the membrane receptor protein GFRA1 is frequently upregulated in many cancers, which can promote cancer development by activating the classic RET-RAS-ERK and RET-RAS-PI3K-AKT pathways. Several therapeutic anti-GFRA1 antibody-drug conjugates are under development. Demethylation (or hypomethylation) of *GFRA1* CpG islands (dmGFRA1) is associated with increased gene expression and metastasis risk of gastric cancer. However, it is unknown whether dmGFRA1 affects the metastasis of other cancers, including colon cancer (CC).

AIM
To study whether dmGFRA1 is a driver for CC metastasis and GFRA1 is a potential therapeutic target.

METHODS
CC and paired surgical margin tissue samples from 144 inpatients and normal colon mucosal biopsies from 21 noncancer patients were included in this study. The methylation status of *GFRA1* islands was determined by MethyLight and denaturing high-performance liquid chromatography and bisulfite-sequencing. Kaplan-Meier analysis was used to explore the effect of dmGFRA1 on the survival of CC patients. Impacts of *GFRA1* on CC cell proliferation and migration were evaluated by a battery of biological assays *in vitro* and *in vivo*. The phosphorylation of AKT and ERK proteins was examined by Western blot analysis.

RESULTS

The proportion of dmGFRA1 in CC, surgical margin, and normal colon tissues by MethyLight was 68.4%, 73.4%, and 35.9% (median; nonparametric test, $P = 0.001$ and < 0.001), respectively. Using the median value of dmGFRA1 peak area proportion as the cutoff, the proportion of dmGFRA1-high samples was much higher in poorly differentiated CC samples than in moderately or well-differentiated samples (92.3%% *vs* 55.8%, Chi-square test, $P = 0.002$) and significantly higher in CC samples with distant metastasis than in samples without (77.8% *vs* 46.0%, $P = 0.021$). The overall survival of patients with dmGFRA1-low CC was significantly longer than that of patients with dmGFRA1-high CC (adjusted hazard ratio = 0.49, 95% confidence interval: 0.24-0.98), especially for 89 CC patients with metastatic CC (adjusted hazard ratio = 0.41, 95% confidence interval: 0.18-0.91). These data were confirmed by the mining results from TCGA datasets. Furthermore, *GFRA1* overexpression significantly promoted the proliferation/invasion of RKO and HCT116 cells and the growth of RKO cells in nude mice but did not affect their migration. *GFRA1* overexpression markedly increased the phosphorylation levels of AKT and ERK proteins, two key molecules in two classic GFRA1 downstream pathways.

CONCLUSION

GFRA1 expression is frequently reactivated by DNA demethylation in CC tissues and is significantly associated with a poor prognosis in patients with CC, especially those with metastatic CC. GFRA1 can promote the proliferation/growth of CC cells, probably by the activation of AKT and ERK pathways. GFRA1 might be a therapeutic target for CC patients, especially those with metastatic potential.

Key words: *GFRA1*; Demethylation; CpG island; Colon cancer; Metastasis; Membrane receptor

Core tip: *GFRA1* reactivation by DNA demethylation is a frequent event in colon cancer (CC) development and that the high level of GFRA1 demethylation in CC tissues is correlated with high metastasis risk of CC and shorter overall survival of patients, especially patients with metastatic CC. We find that GFRA1 overexpression enhances the proliferation and growth of CC cells *in vitro* and *in vivo*, probably by activation of the GFRA1-GDNF downstream pathway. These data indicate that reactivation of *GFRA1* by DNA demethylation is an important prognosis factor for CC and the cancer-related cell membrane protein GFRA1 may be a therapeutic target for CC patients.

INTRODUCTION

Although advances have been made in the treatment of colorectal carcinoma (CRC), it remains the most common gastrointestinal cancer worldwide[1]. CRC is annually diagnosed in 1.4 million individuals and leads to 700000 deaths worldwide[2]. Metastasis is the leading cause of CRC-related death[3]. Although the biological mechanisms associated with CRC metastasis have been extensively studied[4], the sensitivity and specificity of existing clinical biomarkers for predicting the prognosis of CRC patients are not satisfactory. Recognition of specific biomarkers is important for predicting prognosis, including metastasis, of colorectal cancer. Molecular therapy targets for patients with metastatic CRC are also urgently needed.

GFRA1 is a cell surface membrane receptor for glial cell-derived neurotrophic factor (GDNF)[5,6]. The GDNF-GFRA1 complex binds to and activates the tran-

smembrane RET proto-oncogene receptor, induces the phosphorylation of RET tyrosine residues, and activates the RAS-ERK and PI3K-AKT signaling pathways, thus mediating the development of the nervous system and kidneys, as well as cancer growth[6-9]. The *GFRA1* gene is not only normally expressed in neural cells, especially in enteric neurons, but is also abnormally overexpressed in many cancers[9-17]. *GFRA1* overexpression can affect multiple biological behaviors of cancer cells, including proliferation, metastasis, and perineural invasion. *GFRA1* overexpression is associated with a poor overall survival (OS) of patients with pancreatic or breast cancer[12,16]. Anti-GFRA1 autoantibodies can be detected in patients with luminal A (hormone receptor-positive) breast cancer[18,19]. Apparently, the cancer-associated GFRA1 protein is a potential therapeutic target. Several preclinical anti-GFRA1 antibody-drug conjugates for breast cancer treatment have been developed[20,21].

It is well known that the methylation of CpG islands around the transcription start site (TSS-CGIs) epigenetically inactivates gene transcription, and TSS-CGI demethylation is essential for methylated gene reactivation. Our recent studies have shown that *GFRA1* alleles are epigenetically silenced by the methylation of *GFRA1* TSS-CGI (mGFRA1) in many normal non-nervous cells in adult tissues and are abnormally reactivated in cancer cells by the demethylation (or hypomethylation) of the *GFRA1* TSS-CGI (dmGFRA1)[22]. The presence of dmGFRA1 was consistently found to be associated with an increased metastasis risk of gastric carcinoma and short OS in multiple cohorts in China, Japan, and Korea[22]. The results of our prospective study further showed that dmGFRA1 could be a potential biomarker for prediction of metastasis of gastric carcinoma in Chinese patients[23]. However, no studies have reported the impacts of the reactivation of *GFRA1* expression by dmGFRA1 on CRC progression.

In this study, we examined the demethylation status of TSS-CGIs in *GFRA1* alleles in colon carcinoma (CC) and paired surgical margin (SM) tissue samples and normal colon mucosal biopsy samples from noncancer patients. We observed that *GFRA1* was significantly demethylated in both CC and SM tissues compared with that in normal colon biopsies and that the high dmGFRA1 level was significantly correlated with poor differentiation, metastasis, and short OS for CC patients, especially those with metastatic CC. GFRA1 overexpression could promote the proliferation/growth of CC cells *in vitro* and *in vivo*, probably by increasing the phosphorylation levels of two key proteins ERK and AKT in two classical GDNF-GFRA1 downstream pathways in CC cells.

MATERIALS AND METHODS

Human colon samples
CC and paired SM (> 5 cm from the cancerous mass) tissue samples and related clinicopathological information were obtained from 144 patients at Peking University Cancer Hospital. Normal colon mucosal biopsies from 21 noncancer patients from the same hospital were also included in this study. The Institutional Review Board of the Peking University Cancer Hospital and Institute approved the study, and all of the patients provided written informed consent.

Cell lines and culture
The human CC cell line HCT116 was kindly provided by Professor Yuanjia Chen at Peking Union Medical College Hospital, and RKO was purchased from American Type Culture Collection. The HEK293FT cell line was provided by Dr. Zhang ZQ at Peking University Cancer Hospital and Institute. These cell lines were cultured in RPMI 1640 medium (Gibco, GrandIsland, NY, United States) containing 10% fetal bovine serum (FBS; Gibco) and 1% penicillin-streptomycin (Gibco), and maintained at 37 °C in a 5% CO_2-containing atmosphere. These cell lines were tested and authenticated by Beijing JianLian Genes Technology Co., LTD before they were used in this study. STR patterns were analyzed using the Goldeneye 20A STR Identifiler PCR Amplification Kit as we previously reported[22].

More human cell lines were used in the pilot study, including the gastric cell lines BGC823, GES1, MGC803, and SGC7901, cervical cancer cell lines HeLa and Siha, and breast cancer cell line MCF7, kindly provided by Dr. Yang K; the gastric cancer cell line AGS and lung cancer cell line H1299 provided by Dr. Shou CC; the lung cancer cell line A549 provided by Dr. Zhang ZQ at Peking University Cancer Hospital; the gastric cell line MKN74 provided by Dr. Yashuhito Y at Tokyo Medical and Dental University; the prostate cancer cell line PC-3 purchased from Cell Line Bank, Chinese Acad Med Sci; the liver cancer cell line HepG2 provided by Dr. Zhang ZQ; the gastric cancer cell line MKN45 purchased from National Laboratory Cell Resource Sharing

Platform; and the colon cancer (CC) cell lines Colo205 and SW480 provided by Professor Chen YJ at Peking Union Medical College Hospital. A549, BGC823 GES1, H1299, HepG2, MGC803, MKN45, MKN74, and SGC7901 cells were cultured in RPMI1640 medium with 10% FBS. Colo205, HeLa, MCF7, Siha, and SW480 cells were cultured in DMEM with 10% FBS. AGS and PC3 cells were cultured in F12 medium with 10% FBS. AGS and PC3 cells were cultured in F12 medium with 10% FBS.

The Cancer Genome Atlas methylation and transcriptome dataset mining

The methylation information on 31 CpG sites within the *GFRA1* TSS-CGI (by the 450K methylation array) in CC and SM samples from 268 of 454 patients and related clinical information were downloaded from the Cancer Genome Atlas (TCGA) database. OS information was available for 190 patients. The methylation level for each CpG site was expressed using the β value, calculated as $M/(M+U)$, where M is the signal from methylated beads, and U is the signal from unmethylated beads at the targeted CpG site. When the β value for a CpG site was < 0.2, it was classified as demethylation-positive CpG (dmCpG). The total number of dmCpG sites was used to represent the *GFRA1* demethylation level for each sample. The median dmCpG number of 2 for the 268 samples was used as the cutoff value to define dmGFRA1. A sample containing ≥ 2 dmCpG sites was classified as dmGFRA1-high; otherwise, dmGFRA1-low (Table S1). The information on the *GFRA1* mRNA level in CC samples from 453 patients was also downloaded from the TCGA database. The OS information for 350 patients was used in the online OS analysis at the website (bioinformatica. Mty.itesm.mx: 8080/Biomatec/SurvivaX.Jsp)[24].

GFRA1 viral expression vector supernatant and transfection

GFRA1 transcript isoform b (*GFRA1b*, 1380 nt) is the main mature mRNA for this gene in cancer[7,25]. Therefore, the full-length human *GFRA1b* viral expression vector supernatant (pLenti-GFRA1b) was purchased from Obio Technology Corp (Cat. no.CK1116, Shanghai, China). The *GFRA1b* expression viral supernatant or mock viral supernatant control was used to transfect HCT116 and RKO cells following the manufacturer's instructions. To obtain stably-transfected cells, we selected the transfected cells by culturing them in medium containing 0.5 μg/mL puromycin (Sigma, St Louis, MO, United States) for at least two weeks after transfection.

Quantitative RT-PCR

Total RNA was extracted using the Ultrapure RNA Kit (Beijing ComWin Biotech Co., Ltd, China) and the quality and concentration of RNA samples were monitored using the Nanodrop 2000 system (Thermo Fisher Scientific, Waltham, MA, United States). Qualified RNA samples were used to synthesize cDNA using the Trans-Script First-Strand cDNA Synthesis SuperMix (TransGen Biotech, Beijing, China). *GFRA1* mRNA 150-bp amplicon was detected by quantitative RT-PCR (qRT-PCR) using a primer set (forward, 5'-GATATATTCC GGGTGGTCCC ATTC-3', and reverse 5'-GGTGCACGGG GTGATGTACGC-3') and SYBR Green PCR master mix reagents (Roche, Mannheim, Germany) at an annealing temperature of 58.5 °C on an ABI-7500 platform[22]. *GFRA1* mRNA levels were normalized to *Alu* reference RNA as previously reported[25,26]. The relative mRNA level was calculated using the classic ΔΔCt method. Each sample was analyzed in triplicate.

DNA extraction and bisulfite conversion of genomic DNA

Genomic DNA was extracted using the QIAamp DNA Mini Kit (Qiagen, Cat# 51306, Hiden, Germany). Bisulfite conversion was performed by adding 5 M sodium bisulfite to 1.8 μg DNA samples[27].

Hot-start PCR, bisulfite-sequencing, and denaturing high-performance liquid chromatography analysis

A CpG-free universal primer set (forward, 5'-GGTGTTGGAA ATTTTTTAAAGG-3' and reverse, 5'-AAAACACTTC TTCCTTCCACAT-3') and bisulfite-modified DNA were used to amplify both methylated and demethylated *GFRA1* TSS-CGIs at an annealing temperature of 55.0 °C[22]. The PCR products were clone-sequenced and then analyzed quantitatively by denaturing high-performance liquid chromatography (DHPLC) using the WAVE DNA Fragment Analysis System[22,28]. Briefly, 522-bp PCR products of methylated and demethylated *GFRA1* were separated using a DNASep analytical column (Transgenomic) at a partial denaturing temperature of 55.5 °C. Genomic DNA obtained from blood samples with and without *M.sssI* methylation was used as the mGFRA1- and dmGFRA1-positive controls, respectively. The peak areas corresponding to the mGFRA1 and dmGFRA1 products were used to calculate the proportion of dmGFRA1 (the proportion of dmGFRA1-peak area = dmGFRA1-peak area/the sum of the dmGFRA1-peak and mGFRA1-peak areas). When a

dmGFRA1-peak was detected in a sample, it was defined as dmGFRA1-positive sample; otherwise, dmGFRA1-negative (Table S1).

MethyLight assay

The dmGFRA1 levels in all of tissue samples were detected with the MethyLight assay, a previously established and optimized quantitative assay at our lab[22,27]. The median value of dmGFRA1 proportion for CC tissue samples was used as the cutoff to define dmGFRA1-high and dmGFRA1-low CC (Table S1).

Western blot analysis

Cells were collected and lysed to obtain protein lysates. The resulting proteins were then electrophoresed using a 10% SDS-PAGE gel and transferred onto a PVDF membrane. After blocking with 5% nonfat milk overnight at 4 °C, the membrane was incubated with the corresponding primary antibodies [anti-GFRA1 (AF714), R&D systems, Minneapolis, United States; anti-GAPDH (60004-1), Protein Tech, China; anti-ERK (4695S), anti-p-ERK (4370S), anti-AKT (4691T), and anti-p-AKT (4060T), Cell Signaling Technology, United States] for 1 h at room temperature. The membrane was then washed three times with PBST (PBS with 0.1% Tween-20). After washing, the membrane was incubated with the corresponding horseradish peroxidase-conjugated rabbit anti-goat or mouse IgG at room temperature for 1 h. Signals were visualized using the Immobilon Western Chemiluminescent HRP Substrate Kit (Millipore, United States).

Cell proliferation and migration assays using the IncuCyte platform

HCT116 and RKO cells were seeded in 96-well plates (2000 cells/well, 5 wells/group) and cultured for at least 96 h to obtain the proliferation curves. Cells were photographed every 6 h in a long-term dynamic observation platform (IncuCyte, Essen, MI, United States). Cell confluence was analyzed using IncuCyte ZOOM software (Essen, Ann Arbor, MI, United States). For continuous observation of cell migration, the cells were seeded in 96-well plates at a density of 10000 cells/well and cultured for 24 h. After a scratch wound was created, the cells were washed three times with PBS. The cells were regularly cultured and photographed every 6 h for at least 96 h. The relative wound width was calculated using the same software[29].

Animal experiments

RKO cells stably transfected with the control or *GFRA1b* expression vector were trypsinized, washed twice with PBS, and then subcutaneously injected into the bilateral inguinal regions of female BALB/c mice (body weight 18-20 g; age 6 weeks, Beijing Huafukang Bioscience Co. Inc.; 2×10^6 cells per injection). There were eight mice in each experimental group. On the 29th day post-transplantation, the mice were sacrificed. The tumors were then removed from the mice and weighed.

Statistical analysis

All statistical analyses were performed using SPSS 18.0 software. The Mann–Whitney *U*-test was conducted for non-normally distributed data. Student's *t*-test was used for normally distributed data. The log-rank test was used to compare survival durations between groups. All statistical tests were two-sided, and $P < 0.05$ was considered statistically significant.

RESULTS

Reactivation of GFRA1 expression by DNA demethylation in cancer cells and CC tissues

To study the relationship between dmGFRA1 and *GFRA1* mRNA levels, we first analyzed the demethylation status of *GFRA1* CpG islands in a set of cancer cell lines (n = 20). The peak for dmGFRA1 products was detected in seven cell lines (GES1, HEK293T, PC3, MCF7, A549, and HepG2) using the DHPLC analysis (Figure 1A). Bisulfite sequencing confirmed the DHPLC results (Figure 1B). High levels of *GFRA1* mRNA were detected in five dmGFRA-positive cell lines but not in 15 dmGFRA1-negative cell lines (including the four CC cell lines Colo205, HCT116, RKO, and SW480) ($P < 0.001$, Figure 1C). Correlation analysis showed that the dmGFRA1 proportion was positively and significantly correlated with the *GFRA1* mRNA levels in these cell lines (Spearman's test, R = + 0.33, P = 0.041, Figure 1D). This was confirmed by bioinformatics analysis using TCGA demethylation and expression datasets for 267 CC patients: Higher levels of *GFRA1* mRNA were detected in dmGFRA1-high CC samples than in dmGFRA1-low CC samples (P = 0.005, Figure S1).

Figure 1 Demethylation and expression status of the *GFRA1* gene in human cancer cell lines. A: Chromatograms of methylated and demethylated *GFRA1* (mGFRA1 and dmGFRA1) PCR products for 20 cell lines using denaturing high performance liquid chromatography. Blood DNA with and without *M.sssI* methylation was used as mGFRA1 and dmGFRA1 controls, respectively; B: The results of bisulfate sequencing for four representative cell lines containing only dmGFRA1 alleles or mGFRA1 alleles. Each line represents one clone; each red dot represents one methylated CpG site. The *GFRA1* amplicon containing 42 CpG sites is also displayed at the top; C: Comparison of relative *GFRA1* mRNA levels in 20 cell lines with different demethylation statuses; D: Dot chart for correlation between the levels of dmGFRA1 and *GFRA1* mRNA in these cell lines.

Then, a MethyLight assay established by us was used to determine the dmGFRA1 proportion in tissue samples. Compared with that in the normal colon biopsies from noncancer patients (*n* = 21), the dmGFRA1 peak area proportion in CC and SM samples from inpatients (*n* = 97) was significantly increased (median: 35.9% *vs* 68.4% *vs* 73.4%; Mann-Whitney *U*-test, *P* = 0.001 and < 0.001, Figure 2A). The DHPLC results were confirmed by MethyLight analysis (Pearson correlation: *R* = + 0.676, *P* < 0.001, Figure 2B). Bisulfite-sequencing confirmed these results of five representative CC samples (Figure S2). The mRNA and protein levels of the *GFRA1* gene were significantly higher in the representative SM samples than in the normal biopsies (Figure 2C and 2D). Interestingly, the dmGFRA1, mRNA, and protein levels for the *GFRA1* gene in the SM samples were slightly higher than those in the CC samples. According to the publicly available human protein atlas database[30], relative to the normal colon mucosa, GFRA1 protein was mainly increased in the cytoplasm of stromal cells in immunohistochemical staining analysis (Figure S3). These results indicate that dmGFRA1 is a prevalent event in CC development and is associated with increased gene expression.

GFRA1 demethylation correlates with increased metastasis risk of CC and decreased OS

To study the impact of dmGFRA1 on metastasis of CC, CC and paired SM tissue samples from total 144 inpatients were included in this study. Higher dmGFRA1 levels (by MethyLight) were detected in poorly differentiated CC tissues than in moderately or well-differentiated CC tissues (Mann-Whitney *U*-test, *P* < 0.001, Table S2). To better demonstrate the demethylation difference for the *GFRA1* gene between CC patients with different clinicopathological characteristics and to characterize survival factors, we further subclassified these patients into dmGFRA1-high and dmGFRA1-low groups using the median dmGFRA1 proportion as the cutoff value. The proportion of dmGFRA1-high samples remained significantly higher in the poorly differentiated CC samples than in the moderately or well-differentiated CC samples (92.3% *vs* 45.8%, Chi-square test, *P* = 0.002, Table 1). Most importantly, the

Figure 2 Demethylation and expression status of the *GFRA1* gene in colon carcinoma. A: The demethylated *GFRA1* (dmGFRA1) peak area proportions in normal colon mucosal biopsies from noncancer patients (*n* = 21) as well as CC and SM samples from inpatients (*n* = 97) based on MethyLight analysis; B: Correlation analysis of the methylated *GFRA1* (mGFRA1) levels in colon cancer and paired surgical margin tissue samples from 93 patients by denaturing high performance liquid chromatography and MethyLight; C: *GFRA1* mRNA levels in representative colon tissue samples with different pathological lesions by qRT-PCR analysis; D: GFRA1 protein levels in the representative colon tissue samples with different pathological lesions based on Western blot analysis. The density ratio of GFRA1 to GAPDH is listed below each sample id. Note: The mGFRA1 peak area proportion (%) = 100%-the dmGFRA1 peak area proportion (%). dmGFRA1: Demethylated *GFRA1*; mGFRA1: Methylated *GFRA1*.

proportion of dmGFRA1-high samples was significantly higher in CC tissues with distant metastasis than in those without (P = 0.021, Table 1). A similar difference was also found between CC tissues with and without lymphatic metastasis (P = 0.134). This suggests that *GFRA1* reactivation by DNA demethylation may favor CC metastasis.

Kaplan-Meier survival analysis showed that patients with dmGFRA1-high CC had a shorter OS than patients with dmGFRA1-low CC (log-rank test, P = 0.038, Figure 3A). Multivariate analysis showed that dmGFRA1-low CC was an independent favor survival factor after adjustment for age, sex, CC location, differentiation, presence of vascular embolus, local invasion, and metastasis [adjusted hazard ratio (HR) = 0.49, 95% confidence interval (CI): 0.24-0.98, P = 0.044, Table 2]. Notably, sub-stratification analysis revealed that dmGFRA1-low CC was also a significant factor for good OS in 89 CC patients with distant or lymphatic metastasis (log-rank test, P = 0.035, Figure 3B; adjusted HR = 0.41, 95%CI: 0.18-0.91, P = 0.029, Table 2).

These data were confirmed by the analysis results using TCGA datasets. Higher levels of *GFRA1* mRNA were detected in CC samples with vascular embolus than in those without (Mann-Whitney *U*-test P = 0.039, Table S3). The proportion of samples with high *GFRA1* expression was also slightly higher in CC tissues with distant metastasis than in those without (59.4% *vs* 47.5%, Chi-square test, P = 0.080). Kaplan-Meier survival analysis indicated that patients with dmGFRA1-high and *GFRA1* expression-high CC had a shorter OS than patients with dmGFRA1-low and *GFRA1* expression-low CC, but this difference was not statistically significant (Figure S4). Moreover, patients with *GFRA1* expression-high CC had a shorter OS than patients with *GFRA1* expression-low CC among the 350 CC patients in TCGA (P < 0.005; HR = 2.95, 95%CI: 1.26-4.17, Figure S5).

GFRA1 overexpression promotes the proliferation of CC cells *in vitro*

GFRA1b is the main *GFRA1* mRNA isoform in gastrointestinal cancers[25]. To study the

Table 1 Comparison of *GFRA1* demethylation-high proportion by MethyLight for colon carcinoma tissues from 144 patients with various clinicopathological characteristics

		dmGFRA1[1]-high cases	dmGFRA1-low cases	dmGFRA1-high proportion (%)	*P* value[1]
Age (yr)	< 60	35	25	58.3	0.091
	≥ 60	37	47	44.0	
Sex	Male	42	46	47.7	0.494
	Female	30	26	53.6	
Location	Sigmoid	33	40	45.2	0.243
	Others	39	32	54.9	
Differentiation	Poor	12	1	92.3	0.002[2]
	Moderate/well	62	69	45.8	
Vascular embolus	Negative	58	65	47.2	0.098
	Positive	14	7	66.7	
pTNM stage	I/II	33	39	45.8	0.314
	III/IV	38	32	54.3	
Local invasion	T1-2	5	6	45.5	
	T3	44	27	62.0	0.004[3]
	T4	22	38	36.7	
Lymphatic metastasis	N0	32	41	43.8	0.134
	N1-3	40	31	56.3	
Distant metastasis	M0	58	68	46.0	0.021[2]
	M1	14	4	77.8	

[1]Chi-square test;
[2]Fisher's exact test;
[3]T3 *vs* T4; dmGFRA1: Demethylation *GFRA1*.

effect of *GFRA1b* on the proliferation and migration of CC cells, we stably transfected RKO and HCT116 cells with human *GFRA1b*-encoding lentiviral vectors (Figure 4A). The effects of *GFRA1b* on biological behaviors of cells were examined using a long-term dynamic observation platform (IncuCyte). The results showed that the proliferation of RKO and HCT116 cells was significantly increased by *GFRA1b* overexpression (Figure 4B). Although *GFRA1b* overexpression did not affect the migration of these cells based on wound-healing analysis (Figure 4C), however, it promoted the invasion of both cell lines (Figure 4D). Because the *GFRA1* gene is silenced by DNA methylation in any of the tested CC cell lines (SW480, Colo205, HCT116, and RKO; Figure 1A and 1B), we did not study the effect of downregulation of *GFRA1* expression on the biological behavior of CC cells.

GFRA1 overexpression promotes the growth of human CC cells in nude mice

To further investigate whether *GFRA1b* overexpression could promote the growth of CC cells *in vivo*, we subcutaneously injected RKO cells stably transfected with the *GFRA1b* or empty control vector into the bilateral inguinal regions of female BALB/c mice (eight mice per group). Tumor establishment was observed in all eight mice injected with *GFRA1b*-expressing RKO cells but in only four of eight mice injected with RKO cells without *GFRA1b* expression on the 29th day post-transplantation (Figure 5A). The average tumor weight in the *GFRA1b*-expressing group was significantly higher than that in the control group (median, 0.518 g *vs* 0.161 g, *P* = 0.036) (Figure 5B). The GFRA1 protein was detected at a high level in a representative tumor from the *GFRA1b*-expressing group using the Western blot analysis (Figure 5C).

GFRA1 overexpression increases the phosphorylation of ERK and AKT proteins

To explore the effect of *GFRA1b* overexpression on GDNF-GFRA1 downstream signaling pathways in CC cells, we analyzed the phosphorylation status of ERK and AKT proteins, two important molecules in the classic GDNF-GFRA1 downstream pathways (Figure 6A) in RKO and HCT116 cells with and without *GFRA1b* overexpression. The results of Western blot analysis showed that the phosphorylation levels of ERK and AKT proteins (p-AKT and p-ERK) in the GFRA1b-expressing cells were higher than those in the control cells, although the total amounts of AKT and ERK proteins were not changed in either cell line (Figure 6B). This suggests that

Table 2 Results of multivariate analysis for survival factors in colon cancer patients				
	All patients (*n* = 144)		**Patients with metastatic CC (*n* = 89)**	
	Adjusted HR (95%CI)	***P* value**	**Adjusted HR (95%CI)**	***P* value**
Low dmGFRA1	0.49 (0.24-0.98)	0.044	0.41 (0.18-0.91)	0.029
Age	1.68 (0.83-3.40)	0.147	1.69 (0.77-3.73)	0.191
Sex	1.45 (0.76-2.76)	0.256	1.44 (0.71-2.91)	0.317
Location	2.60 (1.32-5.14)	0.006	3.22 (1.48-7.01)	0.003
Differentiation	1.95 (0.65-5.89)	0.235	2.02 (0.62-6.61)	0.246
Vascular embolus	0.32 (0.15-0.68)	0.003	0.33 (0.15-0.74)	0.007
Local invasion	1.27 (0.71-2.28)	0.421	1.16 (0.60-2.24)	0.668
Metastasis	4.92 (2.04-11.84)	0.000		

CC: Colon cancer; HR: Hazard ratio; CI: Confidence interval.

overexpression of *GFRA1b* could increase the phosphorylation levels of ERK and AKT proteins, indicating activation of the GDNF-GFRA1 downstream pathways in CC cells.

DISCUSSION

Key results
GDNF-GFRA1 binding can induce phosphorylation of the RET protein and subsequently activate SRC, MAPK, AKT, Rho, and other downstream signaling pathways to regulate cell survival, differentiation, proliferation, and migration[5-8]. GFRA1 is overexpressed in a variety of cancers and promotes cancer cell proliferation and migration[9-17]. In our recent studies, we consistently found that the *GFRA1* gene was abnormally reactivated by TSS-CGI demethylation in gastric carcinomas and this alteration could be used as a biomarker for the prediction of metastasis of gastric carcinoma and OS in Chinese, Japan, and Korean patients in both cross section and prospective cohorts[22,23]. In the present study, we further report that demethylation of *GFRA1* TSS-CGIs was a frequent event during CC development and that high dmGFRA1 level could significantly increase the metastasis risk of CC and decrease the OS of patients with metastatic CC, probably by activating the GDNF-GFRA1-RET-RAS pathways.

GDNF-GFRA1 determines enteric neuron number by controlling precursor proliferation[31,32]. Dysfunction and downregulation of the *GFRA1* gene can trigger neuronal death in the colon and cause Hirschsprung's disease[33,34]. As a growth factor, the GFRA1 protein also promotes the proliferation and perineural invasion of pancreatic, breast, and bile duct cancer cells[12,16,35]. We found that *GFRA1* reactivation by TSS-CGI demethylation was associated with increased CC metastasis risk and decreased OS in patients with metastatic CC, and that *GFRA1b* overexpression promoted the growth of CC cells and enhanced the phosphorylation levels of the AKT and ERK1/2 proteins. These results suggest that *GFRA1* reactivation by DNA demethylation may enhance CC metastasis. Anti-GFRA1 antibody-drug conjugates are under development[20,21]. It is worth studying whether the CC membrane protein GFRA1 may serve as a molecular target for the intervention of CC metastasis using these anti-GFRA1 antibody agents in the future.

Generally, both TSS-CGI methylation and mRNA and protein levels are used to represent the expression states of target genes. It is well recognized that the methylation status of TSS-CGIs is epigenetically maintained in adult human cells and that changes in DNA methylation are more stable than mRNA and protein alterations. TSS-CGI methylation or demethylation changes in a small proportion of the cell population can be very sensitively detected. Thus, DNA methylation alterations may be optimal cancer biomarkers[36]. We previously reported that analysis of the GFRA1 protein in gastric carcinomas from 40 patients in a tissue microarray by immunohistochemical staining failed to demonstrate a statistically significant association of the GFRA1 protein level with clinicopathological parameters and patient OS[22]. By mining the TCGA dataset, we observed that the *GFRA1* mRNA level (by cDNA array) was significantly higher in the dmGFRA1-high CC samples (by 450K array) than in the dmGFRA1-low samples (Figure S1) and that high *GFRA1* expression was also a significant factor for poor survival in CC patients (*n* = 350, Fig-

Figure 3 Kaplan-Meier overall survival curves for patient groups with demethylated *GFRA1*-high and demethylated *GFRA1*-low colon cancer. A: For 144 patients; B: For 89 patients with local or distant metastasis. The median *GFRA1* demethylation value by MethyLight was used as the cutoff to define demethylated *GFRA1* (dmGFRA1)-high and dmGFRA1-low samples. The *P* value in the log-rank test is also labeled. dmGFRA1: Demethylated *GFRA1*.

ure S5). While fresh/frozen tissue samples should be used to detect the mRNA level of genes, both fresh and paraffin-fixed tissue samples are suitable for methylation analysis of target CpG islands. Interestingly, significant associations of dmGFRA1 (by MethyLight) with CC differentiation, distant metastasis, and OS were successfully demonstrated among 144 patients, implying that dmGFRA1 is a good biomarker.

In the present study, we also found that the upregulation of *GFRA1b*, the main GFRA1 mRNA isoform in CC tissues, could promote the proliferation or growth of HCT116 and RKO cells *in vitro* and *in vivo*. The increased levels of GDNF-GFRA1 downstream phosphoproteins, p-AKT and p-ERK1/2, in *GFRA1b*-expressing HCT116 and RKO cells indicate that activation of the MAPK signaling pathways by the GFRA1 protein may contribute to the enhancement of proliferation in CC cells.

Strengths and weaknesses of the study

Compared to other studies, our study is the only one that focused on correlation between the dmGFRA1 level and CC metastasis. One of the limitations of our study is that we did not interfere with the expression of *GFRA1* to observe changes of biological behavior by downregulation of *GFRA1* expression, because none of tested colon cell lines highly express GFRA1. Effect of *GFRA1* reactivation by dmGFRA1 on CC metastasis should be confirmed in animal models.

In addition, it was reported that, in addition to CpG methylation, non-CpG methylation was also correlated with gene expression and prognosis of diseases[37-39]. Non-CpG demethylation (or hypomethylation) changes in the *GFRA1* gene was not analyzed in the present study.

Future developments

In this study, we found that DNA demethylation of *GFRA1* TSS-CGIs was associated with the reactivation of gene expression, CC metastasis, and OS of patients. High dmGFRA1 level is a potential biomarker for predicting the prognosis of patients with metastatic CC. A prospective study is expected to confirm our present findings. In addition, it is worth further studying whether dysfunctions of the GFRA1 protein by antibody could prevent metastasis in CC patients.

Figure 4 *GFRA1b* overexpression promotes the proliferation of colon cancer cells *in vitro*. A: *GFRA1* expression status in RKO and HCT116 cells transfected with the pLenti-empty control vector or pLenti-*GFRA1b* vector, determined by Western blot; B: Proliferation curves for RKO and HCT116 cells, determined using the IncuCyte systems; C: Migration curves for RKO and HCT116, determined using the IncuCyte systems. Error bars represent S.D.; [b]$P < 0.01$; D: Invasion curves for RKO and HCT116, determined using the IncuCyte systems. Error bars represent S.D.; [a]$P < 0.05$. Ctrl: Control.

Figure 5 Overexpression of *GFRA1b* promotes the growth of RKO colon cancer cells in nude mice. A: Xenograft tumors in the *GFRA1b*-expressing and negative control (Ctrl) groups on the 29th day post-transplantation. Four mice in the control group did not develop tumors; B: Comparison of the tumor weight in the *GFRA1b*-expressing and negative control groups (0.518 g *vs* 0.161 g; Mann-Whitney *U*-test, $P = 0.036$); C: Expression status of the GFRA1 protein in one representative tumor from the *GFRA1b*-expressing and negative control groups by Western blot. Ctrl: Control.


Figure 6 Effect of *GFRA1b* overexpression on the phosphorylation and expression levels of AKT and ERK proteins in colon cancer cells. A: GDNF-GFRA1-related downstream RET-RAS-PI3K-AKT and RET-RAS-RAF1-MEK1/2-ERK1/2 signaling pathways[6-8]; B: Phosphorylation and expression levels of AKT and ERK proteins in RKO and HCT116 cells with and without *GFRA1* overexpression by Western blot. p-AKT and p-ERK represent phosphorylated AKT and ERK proteins, respectively.

ARTICLE HIGHLIGHTS

Research background

The membrane receptor protein GFRA1 is normally expressed in neural cells in many organs, including the colon. The *GFRA1* gene is abnormally and frequently expressed in cancer cells. Anti-GFRA1 autoantibodies can be detected in patients with breast cancer. Several preclinical

anti-GFRA1 antibody-drug conjugates for breast cancer treatment have been developed.

Research motivation

Recently, we reported that the *GFRA1* gene is reactivated by DNA demethylation in gastric cancer, which could be used to predict cancer metastasis. Because *GFRA1* is normally expressed in neural cells in the colon, it is interesting to study whether *GFRA1* reactivation by DNA demethylation is associated with colon cancer (CC) progression and can be used as a therapy target.

Research objectives

To study whether abnormal *GFRA1* demethylation is a driver for CC metastasis and the membrane protein GFRA1 is a potential therapeutic target.

Research methods

CC tissues from 144 patients were included in this study. The level of *GFRA1* demethylation was analyzed by quantitative methylation-specific PCR and bisulfite-sequencing. A set of *in vitro* and *in vivo* experimental assays were used to evaluate the effect of abnormal *GFRA1* expression on CC development.

Research results

The level of *GFRA1* demethylated alleles was significantly increased during CC development and positively associated with poor CC differentiation, distant CC metastasis, and short OS of CC patients. *GFRA1* overexpression significantly promoted CC cell proliferation and invasion *in vitro* and CC growth in nude mice.

Research conclusions

GFRA1 is frequently reactivated by DNA demethylation in CC tissues. *GFRA1* demethylation may be a driver for CC development. GFRA1 protein might be a therapeutic target for CC patients, especially those with metastatic potential.

Research perspectives

A prospective study is expected to confirm our present findings. It is worth further studying whether dysfunctions of the GFRA1 protein by antibody could prevent CC metastasis.

REFERENCES

1   **Mercier J**, Voutsadakis IA. A Systematic Review and Meta-analysis of Retrospective Series of Regorafenib for Treatment of Metastatic Colorectal Cancer. *Anticancer Res* 2017; **37**: 5925-5934 [PMID: 29061771 DOI: 10.21873/anticanres.12039]

2   **Ferlay J**, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int J Cancer* 2019; **144**: 1941-1953 [PMID: 30350310 DOI: 10.1002/ijc.31937]

3   **Liu X**, Ji Q, Fan Z, Li Q. Cellular signaling pathways implicated in metastasis of colorectal cancer and the associated targeted agents. *Future Oncol* 2015; **11**: 2911-2922 [PMID: 26414153 DOI: 10.2217/fon.15.235]

4   **Liu E**, Kinnebrew G, Li J, Zhang P, Zhang Y, Cheng L, Li L. A Fast and Furious Bayesian Network and Its Application of Identifying Colon Cancer to Liver Metastasis Gene Regulatory Networks. *IEEE/ACM Trans Comput Biol Bioinform* 2019 [PMID: 31581091 DOI: 10.1109/TCBB.2019.2944826]

5   **Cacalano G**, Fariñas I, Wang LC, Hagler K, Forgie A, Moore M, Armanini M, Phillips H, Ryan AM, Reichardt LF, Hynes M, Davies A, Rosenthal A. GFRalpha1 is an essential receptor component for GDNF in the developing nervous system and kidney. *Neuron* 1998; **21**: 53-62 [PMID: 9697851 DOI: 10.1016/s0896-6273(00)80514-0]

6   **Airaksinen MS**, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. *Nat Rev Neurosci* 2002; **3**: 383-394 [PMID: 11988777 DOI: 10.1038/nrn812]

7   **Charlet-Berguerand N**, Le Hir H, Incoronato M, di Porzio U, Yu Y, Jing S, de Franciscis V, Thermes C. Expression of GFRalpha1 receptor splicing variants with different biochemical properties is modulated during kidney development. *Cell Signal* 2004; **16**: 1425-1434 [PMID: 15381258 DOI: 10.1016/j.cellsig.2004.05.006]

8   **Parkash V**, Leppänen VM, Virtanen H, Jurvansuu JM, Bespalov MM, Sidorova YA, Runeberg-Roos P, Saarma M, Goldman A. The structure of the glial cell line-derived neurotrophic factor-coreceptor complex: insights into RET signaling and heparin binding. *J Biol Chem* 2008; **283**: 35164-35172 [PMID: 18845535 DOI: 10.1074/jbc.M802543200]

9   **He R**, Liu P, Xie X, Zhou Y, Liao Q, Xiong W, Li X, Li G, Zeng Z, Tang H. circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a. *J Exp Clin Cancer Res* 2017; **36**: 145 [PMID: 29037220 DOI: 10.1186/s13046-017-0614-1]

10 **Fan TC**, Yeo HL, Hsu HM, Yu JC, Ho MY, Lin WD, Chang NC, Yu J, Yu AL. Reciprocal feedback regulation of ST3GAL1 and GFRA1 signaling in breast cancer cells. *Cancer Lett* 2018; **434**: 184-195 [PMID: 30040982 DOI: 10.1016/j.canlet.2018.07.026]

11 **Cavel O**, Shomron O, Shabtay A, Vital J, Trejo-Leider L, Weizman N, Krelin Y, Fong Y, Wong RJ, Amit M, Gil Z. Endoneurial macrophages induce perineural invasion of pancreatic cancer cells by secretion of GDNF and activation of RET tyrosine kinase receptor. *Cancer Res* 2012; **72**: 5733-5743 [PMID: 22971345 DOI: 10.1158/0008-5472.CAN-12-0764]

12 **Gil Z**, Cavel O, Kelly K, Brader P, Rein A, Gao SP, Carlson DL, Shah JP, Fong Y, Wong RJ. Paracrine regulation of pancreatic cancer cell invasion by peripheral nerves. *J Natl Cancer Inst* 2010; **102**: 107-118 [PMID: 20068194 DOI: 10.1093/jnci/djp456]

13 **Borrego S**, Fernández RM, Dziema H, Japón MA, Marcos I, Eng C, Antiñolo G. Evaluation of germline

sequence variants of GFRA1, GFRA2, and GFRA3 genes in a cohort of Spanish patients with sporadic medullary thyroid cancer. *Thyroid* 2002; **12**: 1017-1022 [PMID: 12490080 DOI: 10.1089/105072502320908367]

14   **Frisk T**, Farnebo F, Zedenius J, Grimelius L, Höög A, Wallin G, Larsson C. Expression of RET and its ligand complexes, GDNF/GFRalpha-1 and NTN/GFRalpha-2, in medullary thyroid carcinomas. *Eur J Endocrinol* 2000; **142**: 643-649 [PMID: 10822229 DOI: 10.1530/eje.0.1420643]

15   **Wiesenhofer B**, Stockhammer G, Kostron H, Maier H, Hinterhuber H, Humpel C. Glial cell line-derived neurotrophic factor (GDNF) and its receptor (GFR-alpha 1) are strongly expressed in human gliomas. *Acta Neuropathol* 2000; **99**: 131-137 [PMID: 10672319 DOI: 10.1007/pl00007416]

16   **Wu ZS**, Pandey V, Wu WY, Ye S, Zhu T, Lobie PE. Prognostic significance of the expression of GFRα1, GFRα3 and syndecan-3, proteins binding ARTEMIN, in mammary carcinoma. *BMC Cancer* 2013; **13**: 34 [PMID: 23351331 DOI: 10.1186/1471-2407-13-34]

17   **He S**, Chen CH, Chernichenko N, He S, Bakst RL, Barajas F, Deborde S, Allen PJ, Vakiani E, Yu Z, Wong RJ. GFRα1 released by nerves enhances cancer cell perineural invasion through GDNF-RET signaling. *Proc Natl Acad Sci USA* 2014; **111**: E2008-E2017 [PMID: 24778213 DOI: 10.1073/pnas.1402944111]

18   **Evans RL**, Pottala JV, Egland KA. Classifying patients for breast cancer by detection of autoantibodies against a panel of conformation-carrying antigens. *Cancer Prev Res (Phila)* 2014; **7**: 545-555 [PMID: 24641868 DOI: 10.1158/1940-6207.CAPR-13-0416]

19   **Evans RL**, Pottala JV, Nagata S, Egland KA. Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality. *BMC Cancer* 2018; **18**: 119 [PMID: 29386014 DOI: 10.1186/s12885-018-4022-5]

20   **Bhakta S**, Crocker LM, Chen Y, Hazen M, Schutten MM, Li D, Kuijl C, Ohri R, Zhong F, Poon KA, Go MAT, Cheng E, Piskol R, Firestein R, Fourie-O'Donohue A, Kozak KR, Raab H, Hongo JA, Sampath D, Dennis MS, Scheller RH, Polakis P, Junutula JR. An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast Cancer. *Mol Cancer Ther* 2018; **17**: 638-649 [PMID: 29282299 DOI: 10.1158/1535-7163.MCT-17-0813]

21   **Bosco EE**, Christie RJ, Carrasco R, Sabol D, Zha J, DaCosta K, Brown L, Kennedy M, Meekin J, Phipps S, Ayriss J, Du Q, Bezabeh B, Chowdhury P, Breen S, Chen C, Reed M, Hinrichs M, Zhong H, Xiao Z, Dixit R, Herbst R, Tice DA. Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer. *Oncotarget* 2018; **9**: 22960-22975 [PMID: 29796165 DOI: 10.18632/oncotarget.25160]

22   **Liu Z**, Zhang J, Gao Y, Pei L, Zhou J, Gu L, Zhang L, Zhu B, Hattori N, Ji J, Yuasa Y, Kim W, Ushijima T, Shi H, Deng D. Large-scale characterization of DNA methylation changes in human gastric carcinomas with and without metastasis. *Clin Cancer Res* 2014; **20**: 4598-4612 [PMID: 25009298 DOI: 10.1158/1078-0432.CCR-13-3380]

23   **Liu Z**, Cheng X, Zhang L, Zhou J, Deng D, Ji J. A panel of DNA methylated markers predicts metastasis of pN_0M_0 gastric carcinoma: a prospective cohort study. *Br J Cancer* 2019; **121**: 529-536 [PMID: 31431673 DOI: 10.1038/s41416-019-0552-0]

24   **Aguirre-Gamboa R**, Gomez-Rueda H, Martínez-Ledesma E, Martínez-Torteya A, Chacolla-Huaringa R, Rodriguez-Barrientos A, Tamez-Peña JG, Treviño V. SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. *PLoS One* 2013; **8**: e74250 [PMID: 24066126 DOI: 10.1371/journal.pone.0074250]

25   **Peng XU**, Liu Z, Wei LI, Wang C, Xiaodan HA, Xie J, Zhang J. The mRNA Expression of Different Splice Variants of GFRa1 in Gastric Cancer and Colon Cancer Development Process. Journal of Shihezi University. 2015; 727-731 [DOI: 10.13880/j.cnki.65-1174/n.2015.06.012]

26   **Zheng X**, Zhou J, Zhang B, Zhang J, Wilson J, Gu L, Zhu B, Gu J, Ji J, Deng D. Critical evaluation of Cbx7 downregulation in primary colon carcinomas and its clinical significance in Chinese patients. *BMC Cancer* 2015; **15**: 145 [PMID: 25881303 DOI: 10.1186/s12885-015-1172-6]

27   **Liu Z**, Zhou J, Gu L, Deng D. Significant impact of amount of PCR input templates on various PCR-based DNA methylation analysis and countermeasure. *Oncotarget* 2016; **7**: 56447-56455 [PMID: 27487147 DOI: 10.18632/oncotarget.10906]

28   **Deng D**, Deng G, Smith MF, Zhou J, Xin H, Powell SM, Lu Y. Simultaneous detection of CpG methylation and single nucleotide polymorphism by denaturing high performance liquid chromatography. *Nucleic Acids Res* 2002; **30**: E13 [PMID: 11809901 DOI: 10.1093/nar/30.3.e13]

29   **Tian W**, Du Y, Ma Y, Gu L, Zhou J, Deng D. MALAT1-miR663a negative feedback loop in colon cancer cell functions through direct miRNA-lncRNA binding. *Cell Death Dis* 2018; **9**: 857 [PMID: 30154407 DOI: 10.1038/s41419-018-0925-y]

30   **Uhlén M**, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, Olsson I, Edlund K, Lundberg E, Navani S, Szigyarto CA, Odeberg J, Djureinovic D, Takanen JO, Hober S, Alm T, Edqvist PH, Berling H, Tegel H, Mulder J, Rockberg J, Nilsson P, Schwenk JM, Hamsten M, von Feilitzen K, Forsberg M, Persson L, Johansson F, Zwahlen M, von Heijne G, Nielsen J, Pontén F. Proteomics. Tissue-based map of the human proteome. *Science* 2015; **347**: 1260419 [PMID: 25613900 DOI: 10.1126/science.1260419]

31   **Gianino S**, Grider JR, Cresswell J, Enomoto H, Heuckeroth RO. GDNF availability determines enteric neuron number by controlling precursor proliferation. *Development* 2003; **130**: 2187-2198 [PMID: 12668632 DOI: 10.1242/dev.00433]

32   **Nishiyama C**, Uesaka T, Manabe T, Yonekura Y, Nagasawa T, Newgreen DF, Young HM, Enomoto H. Trans-mesenteric neural crest cells are the principal source of the colonic enteric nervous system. *Nat Neurosci* 2012; **15**: 1211-1218 [PMID: 22902718 DOI: 10.1038/nn.3184]

33   **Uesaka T**, Jain S, Yonemura S, Uchiyama Y, Milbrandt J, Enomoto H. Conditional ablation of GFRalpha1 in postmigratory enteric neurons triggers unconventional neuronal death in the colon and causes a Hirschsprung's disease phenotype. *Development* 2007; **134**: 2171-2181 [PMID: 17507417 DOI: 10.1242/dev.001388]

34   **Camilleri M**, Wieben E, Eckert D, Carlson P, Hurley O'Dwyer R, Gibbons D, Acosta A, Klee EW. Familial chronic megacolon presenting in childhood or adulthood: Seeking the presumed gene association. *Neurogastroenterol Motil* 2019; **31**: e13550 [PMID: 30663199 DOI: 10.1111/nmo.13550]

35   **Iwahashi N**, Nagasaka T, Tezel G, Iwashita T, Asai N, Murakumo Y, Kiuchi K, Sakata K, Nimura Y, Takahashi M. Expression of glial cell line-derived neurotrophic factor correlates with perineural invasion of bile duct carcinoma. *Cancer* 2002; **94**: 167-174 [PMID: 11815973 DOI: 10.1002/cncr.10169]

36   **Deng D**, Liu Z, Du Y. Epigenetic alterations as cancer diagnostic, prognostic, and predictive biomarkers. *Adv Genet* 2010; **71**: 125-176 [PMID: 20933128 DOI: 10.1016/B978-0-12-380864-6.00005-5]

37   **Nicolia V**, Cavallaro RA, López-González I, Maccarrone M, Scarpa S, Ferrer I, Fuso A. DNA Methylation
Profiles of Selected Pro-Inflammatory Cytokines in Alzheimer Disease. *J Neuropathol Exp Neurol* 2017;
76: 27-31 [PMID: 28053004 DOI: 10.1093/jnen/nlw099]

38   **Fuso A**, Ferraguti G, Scarpa S, Ferrer I, Lucarelli M. Disclosing bias in bisulfite assay: MethPrimers
underestimate high DNA methylation. *PLoS One* 2015; **10**: e0118318 [PMID: 25692551 DOI:
10.1371/journal.pone.0118318]

39   **Fuso A**, Scarpa S, Grandoni F, Strom R, Lucarelli M. A reassessment of semiquantitative analytical
procedures for DNA methylation: comparison of bisulfite- and HpaII polymerase-chain-reaction-based
methods. *Anal Biochem* 2006; **350**: 24-31 [PMID: 16445884 DOI: 10.1016/j.ab.2005.12.008]